{"id":42961,"date":"2025-10-09T16:48:05","date_gmt":"2025-10-09T08:48:05","guid":{"rendered":"https:\/\/flcube.com\/?p=42961"},"modified":"2025-10-09T16:48:06","modified_gmt":"2025-10-09T08:48:06","slug":"mirxes-secures-chinas-first-blood%e2%80%91test-approval-for-gastric%e2%80%91cancer-screening","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42961","title":{"rendered":"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening"},"content":{"rendered":"\n<p>Mirxes Holding Company Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/2629:HKG\">HKG: 2629<\/a>) announced that its flagship in\u2011vitro diagnostic (IVD) test, <strong>GASTROClear<\/strong>, has received formal approval from China\u2019s National Medical Products Administration (NMPA). This marks the first blood test authorized by the NMPA for non\u2011invasive gastric\u2011cancer screening, positioning Mirxes at the forefront of early detection technology in one of the world\u2019s largest markets.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-achievement\">Regulatory Achievement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Approval<\/strong> \u2013 GASTROClear is now cleared for use across mainland China, expanding its commercial reach to a market of 1.4\u202fbillion potential patients.<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class<\/strong> \u2013 The product is the first NMPA\u2011approved blood test for gastric\u2011cancer screening, a milestone that could reshape diagnostic pathways.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-innovation\">Product Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>miRNA\u2011Based Detection<\/strong> \u2013 GASTROClear evaluates 12 gastric\u2011cancer\u2011associated microRNA (miRNA) biomarkers, offering a highly specific risk assessment without the need for invasive biopsies.<\/li>\n\n\n\n<li><strong>Global Credentials<\/strong> \u2013 The test received earlier approval in Singapore (2019) and was designated a Breakthrough Device by the U.S. Food and Drug Administration (FDA) in 2023, underscoring its clinical value.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Early Detection Advantage<\/strong> \u2013 By enabling earlier diagnosis, GASTROClear can improve patient outcomes and reduce treatment costs, addressing a critical unmet need in oncology.<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong> \u2013 The NMPA clearance positions Mirxes ahead of domestic competitors and establishes a strong foothold in China\u2019s rapidly expanding IVD sector.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Growth Opportunities<\/strong> \u2013 With regulatory clearance, Mirxes can accelerate commercialization, form strategic alliances with hospitals, and expand into other Asian markets.<\/li>\n\n\n\n<li><strong>Investment Appeal<\/strong> \u2013 The approval enhances Mirxes\u2019 valuation prospects, potentially attracting additional capital for research and development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100900022_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025100900022_c.\"><\/object><a id=\"wp-block-file--media-23536763-45f8-440b-82e3-b35e99ec22ab\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100900022_c.pdf\">2025100900022_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100900022_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-23536763-45f8-440b-82e3-b35e99ec22ab\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in\u2011vitro diagnostic (IVD) test, GASTROClear,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42963,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[16,4245,811,15],"class_list":["post-42961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-cancer","tag-hkg-2629","tag-mirxes","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in\u2011vitro diagnostic (IVD) test, GASTROClear, has received formal approval from China\u2019s National Medical Products Administration (NMPA). This marks the first blood test authorized by the NMPA for non\u2011invasive gastric\u2011cancer screening, positioning Mirxes at the forefront of early detection technology in one of the world\u2019s largest markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42961\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening\" \/>\n<meta property=\"og:description\" content=\"Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in\u2011vitro diagnostic (IVD) test, GASTROClear, has received formal approval from China\u2019s National Medical Products Administration (NMPA). This marks the first blood test authorized by the NMPA for non\u2011invasive gastric\u2011cancer screening, positioning Mirxes at the forefront of early detection technology in one of the world\u2019s largest markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42961\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-09T08:48:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-09T08:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0909.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening\",\"datePublished\":\"2025-10-09T08:48:05+00:00\",\"dateModified\":\"2025-10-09T08:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/0909.webp\",\"keywords\":[\"Cancer\",\"HKG: 2629\",\"Mirxes\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42961#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42961\",\"name\":\"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/0909.webp\",\"datePublished\":\"2025-10-09T08:48:05+00:00\",\"dateModified\":\"2025-10-09T08:48:06+00:00\",\"description\":\"Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in\u2011vitro diagnostic (IVD) test, GASTROClear, has received formal approval from China\u2019s National Medical Products Administration (NMPA). This marks the first blood test authorized by the NMPA for non\u2011invasive gastric\u2011cancer screening, positioning Mirxes at the forefront of early detection technology in one of the world\u2019s largest markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42961\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/0909.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/0909.webp\",\"width\":1080,\"height\":608,\"caption\":\"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42961#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening - Insight, China&#039;s Pharmaceutical Industry","description":"Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in\u2011vitro diagnostic (IVD) test, GASTROClear, has received formal approval from China\u2019s National Medical Products Administration (NMPA). This marks the first blood test authorized by the NMPA for non\u2011invasive gastric\u2011cancer screening, positioning Mirxes at the forefront of early detection technology in one of the world\u2019s largest markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42961","og_locale":"en_US","og_type":"article","og_title":"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening","og_description":"Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in\u2011vitro diagnostic (IVD) test, GASTROClear, has received formal approval from China\u2019s National Medical Products Administration (NMPA). This marks the first blood test authorized by the NMPA for non\u2011invasive gastric\u2011cancer screening, positioning Mirxes at the forefront of early detection technology in one of the world\u2019s largest markets.","og_url":"https:\/\/flcube.com\/?p=42961","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-09T08:48:05+00:00","article_modified_time":"2025-10-09T08:48:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0909.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42961#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42961"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening","datePublished":"2025-10-09T08:48:05+00:00","dateModified":"2025-10-09T08:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42961"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42961#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0909.webp","keywords":["Cancer","HKG: 2629","Mirxes","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42961#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42961","url":"https:\/\/flcube.com\/?p=42961","name":"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42961#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42961#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0909.webp","datePublished":"2025-10-09T08:48:05+00:00","dateModified":"2025-10-09T08:48:06+00:00","description":"Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in\u2011vitro diagnostic (IVD) test, GASTROClear, has received formal approval from China\u2019s National Medical Products Administration (NMPA). This marks the first blood test authorized by the NMPA for non\u2011invasive gastric\u2011cancer screening, positioning Mirxes at the forefront of early detection technology in one of the world\u2019s largest markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42961#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42961"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42961#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0909.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0909.webp","width":1080,"height":608,"caption":"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42961#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mirxes Secures China\u2019s First Blood\u2011Test Approval for Gastric\u2011Cancer Screening"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0909.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42961"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42961\/revisions"}],"predecessor-version":[{"id":42964,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42961\/revisions\/42964"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42963"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}